Cordycepin Regulates GSK-3b/b-Catenin Signaling in

Background: Leukemia stem cells (LSCs) are a limitless cell source for the initiation and maintenance of leukemia. Activation of the Wnt/b-catenin pathway is required for the survival and development of LSCs. Therefore, targeting b-catenin is considered a therapeutic strategy for the treatment of leukemia. The goal of this study was to explore whether cordycepin, an active component of the traditional medicine Cordyceps sinensis, regulates b-catenin expression in leukemia cells. Methodology and Principal Findings: In this study, we found that cordycepin significantly suppressed cell proliferation in all malignant cancer cells, including U937, K562, A549, HepG2, SK-Hep1 and MCF7 in a dose-dependent manner. However, cordycepin reduced b-catenin levels in U937, K562 and THP1 leukemia cells and had no effect on other solid cancer cells. In addition, treatment with cordycepin significantly suppressed leukemia colony formation in soft agar assay. Cordycepin enhanced proteasome-dependent degradation and inhibited nuclear translocation of b-catenin in leukemia cells. Cordycepin-reduced b-catenin stability was restored by the addition of a pharmacological inhibitor of GSK-3b, indicating that cordycepin-suppressed b-catenin stability is mediated by the activation of GSK-3b. Furthermore, cordycepin abolished the effect of Wnt3a-induced b-catenin in leukemia cells. In addition, cordycepin-impaired b-catenin is regulated by Akt activation but is not significantly influenced by AMPK or mTOR signal pathways. Significance: Our findings show for the first time that codycepin selectively reduces b-catenin stability in leukemia but no